Madrigal Pharmaceuticals company profile
Company profile
Madrigal Pharmaceuticals has 915 employees and is headquartered in West Conshohocken, United States.
Madrigal Pharmaceuticals, Inc. recorded revenue of $958.4 million in the fiscal year ended December 2025, and its work is concentrated on metabolic dysfunction-associated steatohepatitis, or MASH, a form of liver disease. The biopharmaceutical company develops novel therapeutics for this condition, with a focus on the United States market. Its main product is Rezdiffra, a liver-directed thyroid hormone receptor beta agonist used for treating MASH, which is the basis of its commercial activity.
In the same fiscal year the company posted a net loss of $288.3 million. Both figures are stated in U.S. dollars for the period ended December 31, 2025. The company had 915 employees and is headquartered in West Conshohocken, Pennsylvania.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 1001 Conshohocken State Road, 19428, West Conshohocken
- Employees
- 915
- Chief executive
- William Sibold
- Founded
- 2011
- Fiscal year
- January - December
- Listing
- MDGL · NASDAQ
- Currency
- USD
- ISIN
- US5588681057
- Website
- madrigalpharma.com
Madrigal Pharmaceuticals and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Madrigal PharmaceuticalsMDGL | United States | $9.93B | 915 | -10.7% | — |
| Corcept TherapeuticsCORT | United States | $9.36B | 730 | 0.8% | 190.2 |
| BioMarin PharmaceuticalBMRN | United States | $11.09B | 3,221 | 16.3% | 146.8 |
| Summit TherapeuticsSMMT | United States | $11.32B | 265 | 0.0% | — |
| Bio-TechneTECH | United States | $11.43B | 3,000 | 21.7% | 66.8 |
| Twist BioscienceTWST | United States | $7.4B | 979 | -28.8% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
